Wellington Management Group LLP Buys 602,858 Shares of Evotec SE (NASDAQ:EVO)

Wellington Management Group LLP lifted its position in Evotec SE (NASDAQ:EVO) by 29.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,634,434 shares of the company’s stock after purchasing an additional 602,858 shares during the quarter. Wellington Management Group LLP owned about 0.74% of Evotec worth $9,616,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC bought a new position in Evotec during the second quarter valued at $87,000. Clear Harbor Asset Management LLC purchased a new stake in shares of Evotec during the 3rd quarter valued at about $104,000. Cetera Advisors LLC bought a new position in shares of Evotec in the 1st quarter valued at about $188,000. Mediolanum International Funds Ltd purchased a new position in Evotec in the third quarter worth about $512,000. Finally, DCF Advisers LLC increased its stake in Evotec by 140.5% during the second quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock worth $552,000 after acquiring an additional 67,156 shares during the last quarter. 5.81% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on EVO. Jefferies Financial Group lowered Evotec from a “buy” rating to a “hold” rating and lowered their price objective for the company from $8.70 to $3.80 in a research note on Monday, October 7th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Evotec in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $5.93.

Evotec Stock Performance

Shares of NASDAQ:EVO opened at $4.49 on Monday. The business has a 50 day simple moving average of $4.19 and a two-hundred day simple moving average of $4.14. Evotec SE has a 1 year low of $2.85 and a 1 year high of $12.00. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.